|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72 TWD | +0.98% |
|
+5.26% | -4.76% |
| May. 15 | Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA | CI |
| May. 14 | Polaris Group Announces Change of the Member of Compensation Committee | CI |
Polaris Group announced the submission to TFDA of the protocol amendment submission of Initial Investigational New Drug Application (IND) for the development of ADI-PEG 20 as a treatment for Hepatocellular Carcinoma (HCC) on 04 May 2023. This is a randomized, double-blinded, multi-center trial, and approximately 300 participants will be randomized in the study. The primary endpoint is OS with PFS as a secondary endpoint.
Planned development stages is Phase 3.
| 1st Jan change | Capi. | |
|---|---|---|
| -4.76% | 1.65B | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
POLARIS GROUP 
